Prolific Machines

Prolific describes its team as diverse, with varied career stages and expertise, and says it fosters a collaborative culture focused on transparency and productivity.

Founded in 2020, Prolific is developing a toolkit to control biology. Its team has expertise in optogenetics, cell line development, synthetic biology, bioprocess development, engineering, business development, finance, and operations.

The company advances biologics development and manufacturing with optogenetics-enabled cell line and biomanufacturing solutions for yield, on-target quality, and process control.

Difficult protein production made simple. A next-generation expression system for next-generation therapeutics.

A light-controlled gene-expression platform reportedly delivers roughly twice the performance of standard fed-batch bioprocessing. The result is described as validating optical control as an approach to cell manufacturing.

May 2026 · GEN - Genetic Engineering and Biotechnology NewsNews article

Prolific Machines sets a monoclonal antibody manufacturing record with its light-controlled platform. SOSV reports that the platform delivers yield gains over standard fed-batch bioprocessing.

May 2026 · SOSVNews article

Prolific Machines appoints Christina Perry, a former Forge Biologics executive, as its chief financial officer.

Feb 2025 · Bastille PostNews article

Prolific Machines lands $86.5 million to develop a platform that uses light to control cells and grow biological products.

Jun 2024 · World Bio Market InsightsNews article